SURGERY PARTNERS INC (NASDAQ:SGRY), a leading operator of short-stay surgical facilities, reported its fourth quarter and full-year 2025 financial results on March 2, 2026. The company delivered a modest revenue beat but posted a significant earnings miss, a combination that triggered a sharp negative reaction in the stock price. Alongside the earnings, the company set its financial guidance for 2026 and announced a new share repurchase program.
Quarterly Results vs. Expectations
The fourth quarter presented a mixed financial picture for Surgery Partners. The company surpassed revenue expectations but fell dramatically short on profitability, which appears to be the primary driver of investor concern.
- Revenue: The company reported Q4 revenue of $885 million, a 2.4% year-over-year increase. This figure narrowly exceeded the analyst consensus estimate of approximately $883.8 million.
- Earnings Per Share (EPS): On a non-GAAP basis, Surgery Partners reported earnings of $0.12 per share. This result missed the analyst estimate of $0.306 per share by approximately 60%, representing a substantial earnings shortfall.
Market Reaction and Price Action
The market's response to the earnings report was decisively negative, reflecting disappointment with the profitability miss and cautious forward guidance. In after-hours trading following the announcement, the stock price fell sharply by over 22%. This severe drop effectively erased the modest gains the stock had accumulated over the past month, underscoring the weight investors placed on the quarterly performance and outlook.
2026 Guidance and Shareholder Return Initiative
A key component of the earnings release was the establishment of financial guidance for the full year 2026. The company provided a revenue outlook with a midpoint of $3.4 billion. However, this projection came in approximately 4.5% below the current analyst consensus estimate of $3.63 billion for the year. The guidance shortfall likely contributed to the negative market sentiment, as it suggests management's expectations for growth are more conservative than those of the broader market.
In a move aimed at returning capital to shareholders, Surgery Partners announced a new share repurchase program. The program authorizes the company to buy back up to $150 million of its common stock. Such initiatives are often viewed favorably as a signal of management's confidence in the company's long-term value, though in this instance, it was overshadowed by the earnings and guidance figures.
Press Release Summary
The company's press release highlighted several key points beyond the raw financials:
- Full-Year 2025 Performance: Surgery Partners emphasized its full-year results, though the focus of investor attention remained on the future outlook.
- 2026 Financial Guidance: The establishment of formal revenue guidance for 2026, albeit below Street expectations, provides a benchmark for the coming year.
- Capital Return Program: The authorization of a $150 million share repurchase program was a central announcement, representing a significant commitment of capital.
Looking Ahead
Analyst estimates for the upcoming first quarter of 2026 indicate expectations for a sequential revenue decline to approximately $838.3 million. The market will be watching closely to see if Surgery Partners can stabilize its profitability metrics and work towards achieving its stated annual guidance, which currently sits below Wall Street's projections.
For a detailed breakdown of historical earnings, future estimates, and analyst ratings, readers can review the data available on the Surgery Partners earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investing involves risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
